<?xml version='1.0' encoding='utf-8'?>
<document id="21075975"><sentence text="The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672." /><sentence text="To support drug development and registration, Caco-2 cell monolayer assays have previously been set up and validated to determine whether candidate drugs are substrates or inhibitors of human P-glycoprotein (P-gp)" /><sentence text=" In this study, the drug-drug interaction (DDI) potential of N-(1-{(3R)-3-(3,5-difluorophenyl)-3-[4-methanesulfonylphenyl]propyl}piperidin-4-yl)-N-ethyl-2-[4-methanesulfonylphenyl]acetamide (AZD5672) was assessed accordingly, and a subsequent clinical digoxin interaction study was performed"><entity charOffset="61-189" id="DDI-PubMed.21075975.s3.e0" text="N-(1-{(3R)-3-(3,5-difluorophenyl)-3-[4-methanesulfonylphenyl]propyl}piperidin-4-yl)-N-ethyl-2-[4-methanesulfonylphenyl]acetamide" /><entity charOffset="191-198" id="DDI-PubMed.21075975.s3.e1" text="AZD5672" /><entity charOffset="252-259" id="DDI-PubMed.21075975.s3.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.21075975.s3.e0" e2="DDI-PubMed.21075975.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21075975.s3.e0" e2="DDI-PubMed.21075975.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21075975.s3.e0" e2="DDI-PubMed.21075975.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21075975.s3.e1" e2="DDI-PubMed.21075975.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21075975.s3.e1" e2="DDI-PubMed.21075975.s3.e2" /></sentence><sentence text=" AZD5672 (1-500 μM) demonstrated concentration-dependent efflux across cell monolayers, which was abolished in the presence of ketoconazole and quinidine, identifying AZD5672 as a P-gp substrate"><entity charOffset="127-139" id="DDI-PubMed.21075975.s4.e0" text="ketoconazole" /><entity charOffset="144-153" id="DDI-PubMed.21075975.s4.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.21075975.s4.e0" e2="DDI-PubMed.21075975.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21075975.s4.e0" e2="DDI-PubMed.21075975.s4.e1" /></sentence><sentence text=" In addition, P-gp-mediated digoxin transport was inhibited in a concentration-dependent manner by AZD5672 (IC(50) = 32 μM)" /><sentence text=" Assessment of the calculated theoretical gastrointestinal inhibitor concentration ([I(2)]) and predicted steady-state maximum total plasma inhibitor concentration ([I(1)]) indicated the potential for a DDI at the intestinal but not the systemic level after the predicted therapeutic dose of AZD5672 (100 mg)" /><sentence text=" A clinical study was performed and the plasma pharmacokinetics [observed maximum plasma drug concentration (C(max)) and area under the plasma concentration versus time curve from 0 to 72 h postdose (AUC(0-72 h))] of orally dosed digoxin (0"><entity charOffset="190-198" id="DDI-PubMed.21075975.s7.e0" text="postdose" /><entity charOffset="230-237" id="DDI-PubMed.21075975.s7.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.21075975.s7.e0" e2="DDI-PubMed.21075975.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21075975.s7.e0" e2="DDI-PubMed.21075975.s7.e1" /></sentence><sentence text="5 mg) were found to be unaffected by coadministration of AZD5672 (50 mg) at steady state" /><sentence text=" In contrast, a 150-mg dose of AZD5672 significantly increased digoxin C(max) and AUC(0-72 h) by 1" /><sentence text="82- and 1" /><sentence text="33-fold, respectively" /><sentence text=" Concentration-time profile comparisons indicated that digoxin elimination was unchanged by AZD5672, and the interaction was most likely to have resulted from inhibition of intestinal P-gp leading to increased digoxin absorption"><entity charOffset="55-62" id="DDI-PubMed.21075975.s12.e0" text="digoxin" /><entity charOffset="210-217" id="DDI-PubMed.21075975.s12.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.21075975.s12.e0" e2="DDI-PubMed.21075975.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21075975.s12.e0" e2="DDI-PubMed.21075975.s12.e1" /></sentence><sentence text=" The observed dose-dependent clinically significant interaction was accurately predicted using calculated [I(2)] and in vitro P-gp inhibition data, confirming AZD5672 to be a P-gp inhibitor in vivo" /><sentence text="" /></document>